Subject(s)
Chromatography, High Pressure Liquid , Glycated Hemoglobin/chemistry , Hemoglobins, Abnormal/chemistry , Chromatography, High Pressure Liquid/methods , Chromatography, High Pressure Liquid/standards , DNA Mutational Analysis , Hemoglobinopathies/blood , Hemoglobinopathies/diagnosis , Hemoglobinopathies/genetics , Hemoglobins, Abnormal/genetics , Humans , Male , Mutation , Young AdultSubject(s)
Humans , Male , Middle Aged , Infarction/complications , Infarction/diagnosis , Anemia, Sickle Cell/complications , Anemia, Sickle Cell/diagnosis , Hemoglobinopathies/complications , Infarction/physiopathology , Infarction , Anemia, Sickle Cell , Primary Health Care/methods , Pain Management/methods , Magnetic Resonance Imaging/instrumentation , Magnetic Resonance Imaging/methods , HemoglobinopathiesABSTRACT
BACKGROUND: Hereditary red cell disorders are associated with a protective effect against malaria, which results in an increased prevalence in malaria-endemic areas. Migratory flows from these areas are resulting in a marked increase in such abnormalities in Southern Spain. METHODS: All hemoglobin disorders diagnosed between 1997 and 2010 have been recorded. Since 2008, we have performed systematic screening for hemoglobinopathies on African patients. A high-pressure liquid chromatography system was used as screening method for structural hemoglobinopathies and for separation of hemoglobin (Hb) F and A(2). RESULTS: We detected 666 cases in patients of foreign origin and 308 in native Spanish patients. Thalassemias (thal) are the most frequent disorders amongst the local population: ß-thal minor, 57.1% (176/308); α-thal, 18.2% (56/308), and δß-thal, 7.8% (24/308). In ethnic minorities, there is a huge variety of hemoglobinopathies: heterozygous Hb S, 45% (300/666); heterozygous Hb C, 15% (100/666); ß-thal minor, 13.7% (91/666); α-thal, 10.2% (68/666); Hb SS in 14 patients, and Hb CC in 9 patients. Of the native patients, 14 were found to have Hb AS and 9 Hb AC. CONCLUSION: Given the modern migratory flows, greater knowledge of these disorders is needed by all medical staff, and new practical and cost/time-effective diagnostic approaches have to be devised.
Subject(s)
Erythrocytes , Hemoglobinopathies/diagnosis , Diagnosis, Differential , Female , Hemoglobinopathies/economics , Hemoglobinopathies/epidemiology , Hemoglobinopathies/ethnology , Humans , Male , Retrospective Studies , Spain/epidemiology , Spain/ethnologyABSTRACT
La resistencia a la proteína C activada (RPCa) hereditaria se ha identificado como un importante factor de riesgo para sucesos tromboembólicos, y consiste en una mutación del factor V que lo hace irreconocible para la inhibición por la proteína C activada (Factor V Leiden, FVL). Sin embargo, la RPCa también se describe en pacientes sin FVL (RPCa adquirida) asociada a la presencia de anticoagulante lúpico, embarazo y neoplasias. Describimos un caso de TVP en una mujer de 54 años, sin síntomas digestivos y con marcadores tumorales negativos, que presentaba RPCa y fue diagnosticada un año después de adenocarcinoma de colon. Una vez consiguió remisión completa, se normalizó la RPCa y se descartó que presentara FVL. En el estudio de trombofilia, el hallazgo de RPCa puede verse influida por reactantes de fase aguda o por un proceso neoplásico, por lo que requiere una valoración evolutiva y un rastreo genético del FVL
Hereditary activated protein C resistance (aPCR) has been indentified as an important risk factor for the occurrence of thromboembolic events. It is most frequently hereditary, and caused by a point mutation in factor V, named Factor V Leiden (FVL), which renders it resistant to the anticoagulant action of circulating protein C. However, aPCR can also be found in absence of FVL (acquired aPCR), associated to lupus anticoagulant, pregnancy or neoplasms. We report a case of deep venous thrombosis (DVT) in a 54 year-old woman, with no digestive symptoms and negative screening for biochemical tumor markers, who presented with DVT from FVL-negative aPCR, one year before being diagnosed of colonic adenocarcinoma. Once complete remission of the carcinoma was reached, aPCR returned to normal values. In thrombophilia screening studies, the finding of aPCR may be caused by acute-phase reactants or neoplastic processes, and therefore require evolutive evaluation and genetic search for FVL
Subject(s)
Female , Middle Aged , Humans , Thrombophilia/complications , Thrombophilia/diagnosis , Protein C , Protein C/metabolism , Colectomy/methods , Colonoscopy/methods , Tomography, Emission-Computed/methods , Colonic Neoplasms/diagnosis , Risk Factors , Biomarkers/analysis , Thrombophilia/pathology , Thrombophilia/physiopathologyABSTRACT
Hereditary activated protein C resistance (aPCR) has been identified as an important risk factor for the occurrence of thromboembolic events. It is most frequently hereditary, and caused by a point mutation in factor V, named Factor V Leiden (FVL), which renders it resistant to the anticoagulant action of circulating protein C. However, aPCR can also be found in absence of FVL (acquired aPCR), associated to lupus anticoagulant, pregnancy or neoplasms. We report a case of deep venous thrombosis (DVT) in a 54 year-old woman, with no digestive symptoms and negative screening for biochemical tumor markers, who presented with DVT from FVL-negative aPCR, one year before being diagnosed of colonic adenocarcinoma. Once complete remission of the carcinoma was reached, aPCR returned to normal values. In thrombophilia screening studies, the finding of aPCR may be caused by acute-phase reactants or neoplastic processes, and therefore require evolutive evaluation and genetic search for FVL.
